Current role
Gina Chapman
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Gina Chapman
Entrada Therapeutics, Inc. reported in an 8-K filed December 6, 2023 that Gina Chapman was appointed member of the Audit Committee, effective December 5, 2023. Entrada Therapeutics, Inc. reported in an 8-K filed August 10, 2023 that Gina Chapman was appointed member of the Nominating and Corporate Governance Committee, effective September 1, 2023. Entrada Therapeutics, Inc. reported in an 8-K filed August 10, 2023 that Gina Chapman was appointed Class III director, effective September 1, 2023.
“On December 5, 2023, effective upon the resignation of Mr. Crowley, the Board appointed Gina Chapman as a member of the Audit Committee and Kush M. Parmar, M.D., Ph.D. as a member and the Chair of the Compensation Committee, to fill the newly-created vacancies resulting from Mr. Crowley's resignation, until their respective successors are elected and qualified, or until their earlier death, resignation or removal, or until otherwise determined by the Board.”
“Ms. Chapman was also appointed to serve on the Nominating and Corporate Governance Committee of the Board (the "NCG Committee"), effective September 1, 2023.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2023-12-05–present
-
2023-01-01–2024-04-29
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Entrada Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Kory Wentworth CFO
- Nathan J. Dowden COO
- Bernhardt Zeiher Board Member
- Bernhardt Zeiher, M.D. Board Member
- Kush M. Parmar, M.D., Ph.D. Board Member
- Maha Radhakrishnan Board Member
- Peter S. Kim Board Member
- Peter S. Kim, Ph.D. Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.